Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPCORE FL-1: Epcoritamab + R2 vs R2 in Relapsed or Refractory Follicular Lymphoma
2023-505628-67-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Apr 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 30
01
Overview
Phase 3, randomised, open-label trial of epcoritamab in follicular lymphoma (FL) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Progression-Free Survival and Best Overall Response (CR or PR). Planned start Apr 2024; status: authorised.
02
Drugs
epcoritamab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2023-505628-67-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505628-67-00.